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Abstract: The current study aimed to synthesize new metal coordination complexes with potential
biomedical applications. Metal complexes were prepared via the reaction of isatin-N(4)anti-
pyrinethiosemicarbazone ligand 1 with Cu(II), Ni(II), Co(II), Zn(II), and Fe(III) ions. The obtained
metal complexes 2–12 were characterized using elemental, spectral (1H-NMR, EPR, Mass, IR, UV-Vis)
and thermal (TGA) techniques, as well as magnetic moment and molar conductance measurements.
In addition, their geometries were studied using EPR and UV–Vis spectroscopy. To evaluate the
in vivo anti-cancer activities of these complexes, the ligand 1 and its metal complexes 2, 7 and 9 were
tested against solid tumors. The solid tumors were induced by subcutaneous (SC) injection of Ehrlich
ascites carcinoma (EAC) cells in mice. The impact of the selected complexes on the reduction of tumor
volume was determined. Also, the expression levels of vascular endothelial growth factor (VEGF) and
cysteine aspartyl-specific protease-7 (caspase-7) in tumor and liver tissues of mice bearing EAC tumor
were determined. Moreover, their effects on alanine transaminase (ALT), aspartate transaminase
(AST), albumin, and glucose levels were measured. The results revealed that the tested compounds,
especially complex 9, reduced tumor volume, inhibited the expression of VEGF, and induced the
expression of caspase-7. Additionally, they restored the levels of ALT, AST, albumin, and glucose
close to their normal levels. Taken together, our newly synthesized metal complexes are promising
anti-cancer agents against solid tumors induced by EAC cells as supported by the inhibition of VEGF
and induction of caspase-7.
Molecules 2019, 24, 3313; doi:10.3390/molecules24183313 www.mdpi.com/journal/molecules
Molecules 2019, 24, 3313 2 of 25
Keywords: metal complexes; isatin-N(4)antipyrinethiosemicarbazone; Ehrlich ascites carcinoma;
tumor volume; VEGF; caspase-7
1. Introduction
Cancer is considered one of the most devastating life-threatening disease worldwide. It is
characterized by uncontrolled cell growth and the rapid spread of abnormal cells [1]. Angiogenesis
is a vital regulator of tumor growth, spread and metastasis [2]. Tumor angiogenesis, which is the
development of new blood vessels, is regulated by the production of angiogenic stimulators such as
vascular endothelial growth factor (VEGF). VEGF is a key regulatory factor in the prognosis of various
cancers; therefore, the inhibition of VEGF production is an alternative therapeutic approach for cancer
treatment [3–6].
Chemotherapy, along with surgery, radiation, hormone therapy, and immune therapy, is
used to treat cancer [7]. Despite the success of controlling the tumor growth in several cases,
the incidence and prevelance of cancer is still dramtically increasing and calling for new
chemotherapeutics to be introduced to the pharmaceutical industry and the market [8]. Antipyrine
(2,3-dimethyl-1-phenyl-5-pyrazolone) and its derivatives possess a diverse array of potentially useful
biological properties [9]. Similarly, thiosemicarbazones have demonstrated significant biological
applications, as antitumor [10], antifungal [11], antiviral [12], antibacterial [13] and antimalarial [14]
agents. Previous investigations involving the synthesis, characterization and biological evaluation
of iron(III), cobalt(II), cobalt(III), nickel(II), zinc(II), and copper(II) complexes of 4-formylantipyrine
N(4)-substituted thiosemicarbazones have been reported [15,16].
Based on these results and as a continuation of our ongoing interest in compounds with antitumor
activities, the present study was carried out to synthesize and characterize metal complexes of
isatin-N(4)antipyrinethiosemicarbazone and to evaluate their anti-tumor, anti-angiogenic and apoptotic
activities against solid tumors induced by Ehrlich ascites carcinoma (EAC) cells in mice.
2. Results and Discussion
All the prepared metal complexes, shown in Figure 1, are stable at room temperature,
non-hygroscopic and insoluble in most organic solvents and water, but they are completely soluble in
dimethylformamide (DMF) and dimethylsulfoxide (DMSO). The elemental analyses, physical data, are
listed in Table 1. The elemental analyses confirmed that complexes 2–6, 8 and 10 are formed in a 1:1
molar ratio of the metal ion and ligand, whereas complexes 9, 11 and 12 are formed in a 1:2 molar ratio
of the metal ion and the ligand. Complex 7 is a binuclear complex.
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Table 1. Analytical and physical data of the ligand 1 and its metal complexes 2–11.
No. Molar Ratio/Compound Color m.p. (◦C) F.W. Yield% Analysis (%)/Found (Calcd) Molar Conductance
C H N S
1 HL C20H18N6O2S Yellow 210–212 406.64 94 59.14(59) 5.15(4.43) 20.91(20.66) 7.85(7.87) -
2 HL+CuCl2(1:1),(2:1),(1:2) [CuLCl]·H2O Deep brown 238–240 522.6 79 46.0(46) 4.1(3.64) 16.3(16.10) 6.88(6.13) 10.0
3 HL+CuBr2(1:1) [CuLBr]·3H2O Brown 250 602.5 89 38.81(39.83) 3.54(3.82) 15.02(13.94) 5.03(5.31) 37.9
4 HL+Cu(NO3)2·3H2O (1:1)[Cu(NO3) L]·H2O Brown 247 548.5 80 43.4(43.5) 3.29(3.5) 18(17.9) 6(5.8) 34.3
5 HL+Cu(OAc)2 (1:1) [Cu(OAc) L]·2H2O Brown 212–216 563.5 74 46.12(46.90) 4.82(4.30) 15.13 (14.9) 5.1(5.7) 11.9
6 HL+Cu(ClO4)2(1:1) [Cu(ClO4)L]·2H2O Brown 250–252 604.5 91 38.92(39.7) 3.75(3.48) 14.67(13.91) 5.18(5.29) 70.32
7 HL+CoCl2 (1:1) [CoClL]2·2H2O Brown 258-260 1036 66 47(46.33) 4.17(3.7) 17(16.21) 6.4(6.18) 47.9
8 HL+Co(OAc)2 (1:1) [Co(OAc) L(H2O)]·4H2O Brown Over 300 614.5 75 42.96(41.9) 5.3(5.04) 14.2(13.7) 4.87(5.2) 4.6
9 Hl+NiCl2 (1:1) [NiCl2(HL)2]·4H2O Brown 254–255 1014.9 84 46.84(47.3) 4.94(4.33) 16.95(16.55) 5.89(6.3) 13.5
10 HL+Ni(OAc)2 (1:1) [Ni(OAc) L]·2H2O Brown Over 300 558.9 70 47.76(47.24) 4.19(4.3) 15. 6(15.03) 6.71(5.78) 2.6
11 HL+Zn(OAc)2 (1:1) [ZnL2·H2O Deep yellow Over 300 912.2 69 51.9(52.6) 3.7(4.2) 18.8 (18.42) 6.64 (7) 1.4
12 HL+FeCl3 (1:1) [FeCl2(HL)2]Cl·H2O Deep green 210–212 993.7 78 47.62(48.3) 3.9(3.8) 16.95(16.91) 5.6(6.44) 54.09
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2.1. 1H-NMR Spectra
The 1H-NMR spectra of the ligand 1 and the zinc complex 11 are illustrated in the Supplementary
Materials. The data shows three separate singlets at 12.819, 11.219 and 10.115 ppm, which can
be attributed to the thiosemicarbazide N-N(2)H, the indole N-H moiety and the thiosemicabazide
CS-N(4)-H, respectively [17]. Multiple signals appear in the 7.702–6.876 ppm region, and these can be
attributed to the aromatic protons of the indole and phenyl rings of antipyrine. The other signals for
the ligand at 3.068 (s, 3H) and 2.135 (s, 3H) correspond to the N-CH3 and C-CH3 of the antipyrine
moiety, respectively [15]. The 1H-NMR spectrum of complex 11 does not show a signal corresponding
to N-N(2)H of thiosemicarbazide, suggesting the loss of the thiol proton, and the binding ligand in its
thiol form. The spectrum displays signals attributable to the indole N-H moiety, the CS-N(4)-H of
thiosemicabazide and all the other characteristic signals at the same positions as those of the free ligand.
2.2. Mass Spectra
The mass spectra of ligand 1 and complexes 7, 8, 11, and 12 are shown in the Supplementary
Materials. The molecular ion peak at m/z 406.27 amu in the spectrum of the ligand 1 is consistent
with the molecular weight of its proposed structure. Moreover, the fragmentation pattern shows ion
peaks at m/z 363.47, 291.15, 276.68, 261.69, 223.71, 204.07, 203.30, 145.64, 130.57, 118.18 and 76.3 amu
corresponding to C19H17N5OS, C13H17N5OS, C12H13N5OS, C12H13N4OS, C9H10N4OS, C9H6N3OS,
C11H13N3O, C8H5N2O, C8H5NO, C7H5NO and C6H5 fragments, respectively.
The mas spectrum of complex 7 (F.W. = C40H38N12O6S2Co2Cl2) shows a molecular ion peak at
m/z 999.5 amu, consistent with a molecular weight of 998.8 g/mol, which is the molecular weight
of the complex after the loss of one molecule of hydration water (F.W. = C40H34N12O4S2Co2Cl2).
The spectrophotometer at hand cannot detect molecular ions with molecular weights greater than
1000 g/mol. The fragment ion peaks at m/z 868.9 and 463.9 amu correspond to the formulas
C40H34N12O4S2Co and C20H17N6O2Co.
The mass spectrum of complex 8 (C22H30N6O9SCo, F.W. = 612.5) displays a molecular ion
peak at m/z 612.85 (100%) amu, confirming the suggested structure of the complex. Moreover, the
spectrum shows several peaks, including peaks at m/z 576.23 (94.07), 561.30 (61.93), 541.85 (6.86), and
523.22 (39.20), corresponding to the formula C22H26N6O7SCo, C22H24N6O6SCo, C22H22N6O5SCo, and
C22H20N6O4SCo, respectively, due to the sequential loss of two molecules of water of hydration, another
water of hydration, a final water of hydration, and one coordinated water molecule, respectively.
The mass spectrum of complex 11 (C40H38N12O6S2Zn, F.W. = 911.50) displays a molecular ion
peak at m/z 911.95 (1.19), consistent with the suggested structure.The mass spectrum of complex 12
(C40H38N12O5S2FeCl3, F.W. = 992.50) exhibits a molecular ion peak at m/z 992.50 amu, confirming
the putative molecular weight of the complex. Moreover, the spectrum shows several ion peaks,
including peaks at 973.50 (1.90), 938.30 (12.96), 869.80 (8.27), and 464.40 (2.48) corresponding to the
formula C40H36N12O4S2FeCl3, C40H38N12O5S2FeCl3, C40H38N12O5S2FeCl2, C40H38N12O5S2Fe and
C20H18N6O2SFe, which are attributable to the losses of one water of hydration, an ionisable chloride,
two coordinated chloro ligands and one ligand, respectively.
2.3. The Molar Conductance
The molar conductance values of the metal complexes in DMF (10−3 M) were illustrated in Table 1.
The results showed that none of the complexes except 12 are electrolytes [16], indicating that the anions
in all these complexes are directly bound to the metal ion. Complex 12 gave a molar conductance of
74.5 Ω−1cm2mol−1 attributable to a 1:1 electrolyte, and indicating the presence of a chloride ion in the
outer coordination sphere [18]. The high value of molar conductance of complex 6 may be associated
with the partial displacement of the perchlorato ligand by DMF [15].
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2.4. Infrared (IR) Spectra
The IR spectra of the ligand 1 and its metal complexes 2–12 were shown in Supplementary
Materials. The most diagnostic infrared spectral bands are illustrated in Table 2; the infrared spectrum
of the ligand 1 displays bands at 3442, 3348, 3287, 3251, and 3141 attributable to ν(N-H) absorptions
characteristic of –NH groups [19,20]. The spectrum also displays bands at 1738, 1645, 1688, 1623 and
1595 cm−1. The first band can be assigned to ν(C=O) of the isatin moiety [19,20], and the second
band can be assigned to ν(C=O) of the antipyrine moiety. The latter three bands are associated with
ν(C=N) [21]. The appearance of multiple bands characteristic of ν(C=N) can be explained by the
formation of tautomers secondary to the presence of the isatin carbonyl group and C=S with the
adjacent –NH groups. The absorption band of ν(C=S) (thioamide IV) observed at 881 cm−1 [15] and a
weak band observed at 2650 cm−1, assigned to ν(C-SH), supported the thione-thiol tautomerization
expected from the C=S group with an adjacent proton [22].
The binding mode of the ligand in each metal complex has been deduced by comparing the IR
spectrum of the ligand with that of the corresponding metal complex. In the infrared spectra of all the
complexes, the band characteristic of the ν(C=N) of the isatin moiety is shifted to lower wave numbers
compared to that of the free ligand, indicating the coordination of C=N group with the metal via the
nitrogen atom in all complexes. In the IR spectra of the metal complexes, except for those of 7 and 8,
the bands corresponding to the C=O of the isatin moiety appeared at lower wavenumbers compared
to that of the ligand as a result of the participation of the carbonyl oxygen atom of this group in the
coordination. This band did not shift in the infrared spectra of complexes 7 and 8, indicating that C=O
is not involved in the coordination.
In the infrared spectra of the complexes, except 9, 10 and 12, the absorption band is attributable to
the ν(C=O) of the antipyrine moiety appeared at the same position as that of the ligand, indicating
that this group only participates in coordination to the metal ion in complexes 9, 10 and 12. In the
infrared spectra of all complexes, except 9 and 12, the band corresponding to ν(C=S) appeared at
lower wavenumbers (808–848 cm−1) compared to that of the free ligand, indicating that the C-S group
takes part in the coordination. The appearance of a band at 1622–1560 cm−1, which is assignable to
υ(–N=C-S-), accompanies the shift in the ν(C-S) band. The appearance of the later band indicates the
participation of the thiol form in coordination rather than the thion form, as suggested by the 1H-NMR
spectrum of complex 11. The ν(C=S) bands in the infrared spectra of complexes 9 and 12 were at
the same position as that of the free ligand, indicating that the C=S moiety does not participate in
coordination in complexes 9 and 12.
Complexes 9 and 12 are composed of two ligand molecules that bind to one metal ion, and
their infrared spectra showed that the two ligand molecules have different binding modes. In the
infrared spectra of the complexes 9 and 12, each exhibits four bands at 1735–1737, 1700–1660, 1645 and
1620 cm−1, attributable to the uncoordinated ν(C=O) of the isatin moiety, the coordinated ν(C=O) of
the isatin moiety, the uncoordinated ν(C=O) of the antipyrine moiety and the coordinated ν(C=O) of
the antipyrine moiety, respectively. Moreover, each of the spectra of complexes 9 and 12 displays two
bands corresponding to the ν(C=N) of the isatin moiety at 1595 and 1520 cm−1, which are assignable to
the free uncoordinated C=N and the coordinated C=N, respectively. The above results illustrate that
one of the ligand molecules behaves as a neutral, bidentate ligand and coordinates via the C=N and
C=O groups of the isatin moiety and that the second molecule also behaves as a neutral, bidentate
ligand but coordinates via the C=O and N-H groups of the antipyrine moiety.
The spectra of acetato complexes 5, 8 and 10 show two absorption bands at 1620–1615 and
1372–1333 cm−1, assigned to υ(C=O) and υ(C-O), respectively. The difference between these two bands
is approximately 287−243 cm−1, which indicates that the acetate in these complexes coordinates to
the metal ion as a monodentate ligand [23]. The monodentate coordination of a perchlorate ligand
lowers the symmetry of the system (Td→C3v). The modes of the free perchlorate that were initially
degenerated (υ3 and υ4) are both split into two bands [24]. The infrared spectrum of the perchlorate
[Cu(ClO4)L]·2H2O complex showed that both the υ3 band and υ4 band are split into two bands, at 1118
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and 1085 cm−1 and at 694 and 631 cm−1, respectively, indicating that the perchlorate coordinates to the
metal ion as a monodentate ligand. The infrared spectrum of complex 4, [Cu(NO3)L]·H2O showed
two bands at 1462 and 1382 cm−1, attributable to a monodentate nitrato ligand [25]. The infrared
spectra of the hydrated complexes display a broad band at 3491–3388 cm−1 from ν(OH) of the water
molecule [26]. The IR spectra of all the complexes display a new band at 591–498 cm−1, assigned
to ν(M-N) [27–29], and the spectra of all the metal complexes except 7 and 8 show a new band at
693–589 cm−1, assigned to υ(M-O) [19–29].
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Table 2. IR spectral bands (cm−1) for ligand 1 and its metal complexes 2–12 and their assignments.
No. Ligand/Complexes ν(H2O) ν(N4H) ν(C=O) ν(C=N) ν(C=S) ν(M-O) ν(M-N) ν(OAc/ClO4/NO3
1 Ligand C20H18N6O2S - 3442, 3348, 3287, 3251, 3141 1738 a, 1645 b 1688 a, 1623, 1595 881 - - -
2 [CuClL]·2H2O] 3395 3161, 3100 1702 a, 1645 b 1616, 1539 808 632 498 -
3 [CuBrL]·3H2O 3446 3106 1695 a, 1643(sh) b 1622, 1578 - 614 504 -
4 [Cu (NO3) L]·H2O 3425 3166 1703 a, 1645 b 1620, 1539 808 638 586 1382–1462
5 [Cu(OAc)L]·2H2O 3417 3237 1680 a, 1645 b 1560, 1525 847 595 503 1615, 1333
6 [Cu(ClO4)L]·2H2O 3428 3325, 3170 1628 a, 1645 b 1568, 1516 838 631 505 1085, 1049
7 [CoClL]2·2H2O 3388 3150 1734 a, 1645 b 1600, 1515 840 629 585 -
8 [Co (OAc) L(H2O)]·4H2O 3491, 3422 3196 1734 a, 1645 b 1590, 1545 841 630 540 1619, 1372
9 [NiCl2(HL)2]·4H2O 3441 3280 1735 a, 1660 a, 1645 b. 1610 b 1688, 1620 877 648 591 -
10 [Ni(OAc) L]·2H2O 3445 3310, 3200 1664 a (sh), 1640 b 1580, 1540 829 590 503 1620, 1342
11 [Zn L2]·2H2O 3413 3223 1700 a, 1643 b 1609 848 612 580 -
12 [FeCl2(HL)2]Cl·H2O 3429(s,br) 3280 1737 a, 1700 a, 1645 b, 1610 a 1685, 1620 881 589 512 -
a indigo moiety, b antipyrine moeity, -: indicates no value available.
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2.5. Magnetic and Electronic Spectra
The room-temperature magnetic moments (µeff BM per metal atom) and electronic spectral bands
for the metal complexes in the solid state are described in Table 3. The data showed that the electronic
absorption spectrum of ligand 1 exhibits bands at 268 and 280 nm, attributable to intra-ligand pi→pi*
electronic transitions [15,30]. These bands do not change significantly upon complex formation [31].
The somewhat broad band at 369 nm is assignable to the intra-ligand n→pi* electronic transitions
associated with the combination of the azomethine function of the thiosemicabazone, the thione function
of the thiosemicabazone and the heterocyclic moiety [15,32]. In the spectra of the metal complexes, this
band generally shifts to a higher energy as a result of the participation of the azomethine and/or thiol
groups in coordination [33,34]. In the spectra of the metal complexes, new bands were observed in
the 357–530 nm region due to S(pi)→metal(II,III) charge-transfer processes [35,36], and the spectrum
of bromo complex 3 showed a Br→metal(II) charge-transfer band [37]. Cl→metal(II,III) [38–40]
and O→metal(II,III) [35] charge-transfer bands were generally observed at approximately 333 nm
and were obscured by the stronger intra-ligand transfer bands. Copper(II) complexes 2–6 showed
magnetic moments of 1.76–1.87 BM. These values are close to the spin-only value for one unpaired spin
(~1.73 BM) and indicate that there is no molecular association between the copper(II) ions in the square
planar environment [34,41,42]. The electronic absorption spectra of Cu(II) complexes 2–5 showed
two or three bands at 870–660, 740–631 and 675–580 nm, assignable to the 2B1g(dx2−y2)→2A1g(dz2),
2B1g(dx2−y2)→2B2g(dxy) (υ2) and 2B1g(dx2−y2)→2Eg(dxz,dyz) (υ3) transitions, suggesting a square
planar geometry around the copper(II) ion. Complex 6 displays a broad band at 790 nm that could be
attributed to the abovementioned transitions in the ligands in a square planar geometry around the
copper(II) ion [43–45].
Cobalt(II) complex 7 gave a magnetic moment of 3.1 BM, which is considerably less than
what is expected for high-spin tetrahedral cobalt(II). This unexpected value could be explained by
the occurrence of antiferromagnetic exchange through the chloro bridge linking the two cobalt(II)
ions [46,47]. Complex 8 gave a magnetic moment of 3.7 BM per metal ion, which is consistent with
high-spin tetrahedral cobalt(II) complexes [48]. The electronic spectra of complexes 7 and 8 displayed
a broad band with several features at approximately 675 nm, which is attributable to the 4A2→4T1(P)
(v3) transition in a tetrahedral geometry around the Co(II) ion [15].
The nickel(II) complexes were found to be paramagnetic, which ruled out square planar
configurations. The magnetic moments of nickel(II) complexes 9 and 10 are 2.98 and 3.06 BM,
respectively, corresponding to two unpaired electrons [49], suggesting geometries other than square
planar. The electronic spectra of Ni(II) complexes 9 and 10 showed bands at 950, 690-675 nm
and 560−567 nm, assignable to the 3A2g(F)→3T2g(F)(υ1), 3A2g(F)→3T1g(F)(υ2) and 3A2g(F)→3T1g(P)
transitions, respectively, in an octahedral environment [50–52]. The υ2/υ1 ratios for these complexes
are 1.41 and 1.37, which are below the usual range of 1.5–1.75. These ratios suggest a tetragonally
distorted octahedral geometry around the nickel(II) ions [51,53].
Iron(III) complex 12 gave a magnetic moment of 5.95 BM per metal ion, corresponding to a
high-spin d5 configuration. The electronic spectrum of complex 12 showed strong bands at 391, 450, 530
and 584 nm. The first three bands can be assigned to ligand-to-metal charge-transfer (LMCT) processes.
The last band at 584 nm is broad and of relatively high intensity. The relatively high intensity of this
band can be attributed to overlap with a low-lying ligand charge-transfer band. This is because in the
case of iron(III), the d-d transitions are considered forbidden because they take place between ions
with different multiplicities; examples of such transitions include the 6A1g→4T1g (G), 6A1g→4T2g (G)
and 6A1g→4Eg (G) or 4Eg(D) transitions in tetragonally distorted octahedral Fe(III) environments [54].
The electronic spectrum of the zinc(II) complex showed bands at 396, 440, 491, and 520(sh), which can
be attributed to ligand-to-metal (L→M) charge-transfer processes.
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Table 3. The electronic absorption spectral bands (nm) and magnetic moments of ligand 1 and its metal
complexes 2–12.
No. Compound pi→pi* (nm) n→pi* ChargeTransfer d→d Bands µeff (β.M)
1 HL C20H18N6O2S 268 280, 369 -
2 [CuLCl]·2H2O 291 310, 395 600, 672, 770 1.03
3 [CuLBr]·3H2O 295 325, 445 580, 631 1.1
4 [Cu(NO3) L]·H2O 270 310, 455 520, 574 675, 720 1
5 [Cu(OAc) L]·2H2O 270 310 560, 671 1.11
6 [Cu(ClO4)L]·2H2O 270 363, 400 500(br),770(br) 1.6
7 [CoClL]2·2H2O 260 318, 345 600, 675, 700 0.42
8 [Co(OAc)L(H2O)]·4H2O 290 320 600, 675, 780 3.7
9 [NiCl2(HL)2]·4H2O 290 310, 396 420 500 -
10 [Ni (OAc) L]·2H2O 291 305 567, 950 2.26
11 [ZnL2]·2H2O 280 319, 396 480, 520(sh) - -
12 [FeCl2(HL)2]Cl·H2O 270 300, 391 450 584 4.67
-: indicates no value available.
2.6. EPR Spectra of the Copper(II) Complexes
The EPR spectra of the Cu(II) complexes are illustrated in the Supplementary Materials. The EPR
data of Cu(II) complexes 2–6 in the polycrystalline state at 298 K are listed in Table 4. The EPR spectra
of the Cu(II) complexes have low g1 and gav values, indicating that the bonds have considerable
covalent characteristics [18,55]. The EPR spectra of the Cu(II) complexes other than complex 5
([Cu(L)(OAc)]·2H2O) show rhombic-type distortion with three g values, g1 = 2.189, 2.198, 2.287, and
2.25; g2 = 2.121, 2.079, 2.121, and 2.12; and g3 = 2.057, 1.989, 1.977, and 2.027, respectively. The rhombic
symmetry of these complexes is attributable to the bulkiness of the ligand and to the unequal bond
lengths of the four Cu-S, Cu-N, Cu-O, and Cu-X bonds (X=Cl, Br, NO3 or ClO4) [55]. The g tensors,
which follow g1 > g2 > g3 > 2, are indicative of complexes with a d(x2−y2) ground state. This result is
supported by the value of R (R = (g2 − g1/(g3 − g2) < 1 (= 0.94 − 0.72)), confirming a d(x2−y2) ground
state with covalent bonding character [56,57].
The EPR spectral data of complex 5 demonstrate anisotropic signals with g‖ > g⊥ > 2.0023, which
are indicative of a d(x2−y2) ground state with axial symmetry, resulting in a 2B1g ground state that is
known for Cu2+ complexes [58,59]. These g values are consistent with Cu2+-complex 5 having a square
planar geometry [60,61]. The geometric parameter G, which is a measure of the exchange interaction
between the copper centres in the solid state, was calculated using the equation G = (g‖ − 2.0023)/(g⊥ −
2.0023) for axial and rhombic compounds, g‖ = g1 and g⊥ = g2 + g3/2. If G > 4, the exchange interaction
is negligible, and if it is less than 4, considerable exchange interactions exist [58,62]. Complexes 3, 4,
and 5 have G values > 4, indicating that exchange interactions are negligible, while for complexes
2 and 6, G < 4, suggesting considerable exchange interactions between the Cu(II) centres. Kivelson
and Neiman reported that the g‖-values of Cu2+ complexes can be used to determine the nature of
the copper-ligand bonding. If the g‖-value is smaller than 2.3, the environment is essentially covalent,
while if the value is larger than 2.3, the environment is essentially ionic [63]. For all the synthesized
complexes, g‖ < 2.3, indicating that there is considerable covalent character in the copper-ligand bonds.
According to [45,64,65], the orbital reduction factor (k) and its parallel (k‖) and perpendicular (k⊥)
components were calculated according to the following equations: k‖2 = (g‖ − 2.0023)∆2/8λ0, k⊥2 = (g⊥
− 2.0023) ∆1/2 λ0, k2 = (K‖2 + 2⊥2)/3 where λo is the spin orbit coupling (−828 cm−1) of the free Cu(II) ion,
and ∆1 and ∆2 are the electronic transitions 2B1g→2B2g (dx2−y2→dxy) and 2B1g→2Eg (dx2−y2→dxzdyz),
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respectively. The calculated k‖2, k⊥2 and k2 values in Table 1 showed that for complexes 3–6, k‖ > k⊥,
indicating the presence of significant out-of-plane pi-bonding [66] and confirming that 2B1g is the
ground state for these complexes. For complex 2, k‖ < k⊥, indicating the presence of significant
in-plane pi-bonding [67]. Moreover, when the environment is ionic, k = 1, but if this value is less
than 1, the environment is covalent. These compounds showed k values lower than one, which is
strong evidence of covalent character, which is in agreement with the results obtained from the g‖
values [65,68]. None of the solid-state EPR spectra of the complexes displayed hyperfine structure,
confirming the presence of intermolecular interactions, but these interactions were not strong enough
to overcome the dipolar interactions [69].
Table 4. EPR spectral assignments and bonding parameters for Cu(II) complexes in polycrystalline
state at 298 K.
Parameter Complex 2 Complex 3 Complex 4 Complex 5 Complex 6
g‖ or g1 2.189 2.198 2.287 g‖ = 2.21 2.25
g⊥ or g2, g3 2.121, 2.057 2.079, 1.989 2.121, 1.977 g⊥ = 2.038 2.12, 2.027
g⊥ 2.089 2.034 2.049 2.038 2.074
gav 2.12 2.125 2.128 2.095 2.132
G 2.12 5.82 5.86 5.53 3.38
R 0.94 0.76 0.87 - 0.72
k‖2/k‖ 0.419/0.647 0.468/0.684 0.637/0.798 0.424/0.651 0.554/0.744
k⊥2/k⊥ 0.722/0.850 0.29/0.539 0.391/0.625 0.248/0.498 0.137/0.370
K2/k 0.621/0.788 0.349/0.591 0.473/0.688 0.307/0.554 0.276/0.525
-: indicates no value available.
2.7. Thermal Analysis
The TGA spectra of metal complexes are shown in the Supplementary Materials. The TGA results
of solid complexes 2, 3, 5 and 7–12 are listed in Table 5. The results show an agreement with the
formulae suggested by the analytical, spectral and magnetic data. A general decomposition pattern,
in which the complexes decompose in two or three stages, was observed. The first stage is the loss
of waters by hydration at 29–160 ◦C; the second stage of decomposition corresponds to the loss of
coordinated water molecules at 80–175 ◦C; complex 8 showed a third decomposition stage that is a
result of overlapping processes including the loss of Cl−, Br− or OAc− anions; the loss the ligands to
form metal oxides or metal sulfides mixed with carbon residues; and the oxidation of carbon to carbon
dioxide leaving metal oxides or sulfides.
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Table 5. Thermal (TGA) data for metal complexes 2, 3, 5, and 7–12.
No. Complex Temp.Range (◦C)
Weight Loss
Found (calc)% Assignment
Residual’s
Formula
2 [Cu(L)Cl]·H2O] 30–120213–898
4.10 (3.44)
83.90(84.30)
Loss of water of hydration (1H2O)
Continuous decomposition of complex
[Cu(L)Cl]
CuO
3 [Cu(L)Br]·3H2O 26–75191–763
9.3(8.96)
79.54(80.6)
Loss of water of hydration (3H2O)
Continuous decomposition of complex
[Cu(L)Br]
CuO
5 [Cu(L)OAc]·2H2O 30–109109–800
6.60(6.40)
81.55(82.40)
Loss of water of hydration (2H2O)
Continuous decomposition of complex
[Cu(L)OAc]
CuO
7 [Co(L)Cl]2·2H2O
45–145
195–470
625–660
4.20(3.50)
69.23(70.30)
8.30(8.10)
Loss of water of hydration (2H2O)
Partial decomposition of complex
oxidation of carbon to CO2
[Co(L)Cl]2
2CoS + 7C
2CoS
8 [Co(L)OAc(H2O)]·4H2O
27–80
80–175
195–550
600–898
11.30(11.73)
3.63(2.93)
66.00(66.51)
3.12(3.91)
Loss of water of hydration (4H2O)
Loss of coordinated water (1H2O)
Continuous decomposition of complex to
form metal oxide and carbon
Partial oxidation of carbon
[Co(L)OAc
(H2O)]·CoO + 3C
CoO + 1C
9 [Ni(HL)2Cl2]·4H2O 42–133133–550
7.50(7.10)
77.73(78.85)
Loss of water of hydration (4H2O)
decomposition of complex and formation
of cobalt oxide and carbon
[Ni (HL)2Cl2]·
NiO + 7C
10 [Ni2(L)2(OAc)2]·4H2O
27–75
75–255
255–899
6.00(6.43)
4.50(4.30)
78.30(77.80)
Loss of water of hydration (4H2O)
Loss of one acetato ligand
Decomposition of complex
[Ni2(L)2(OAc)2]
[Ni2(L)2(OAc)]
NiO
11 [Zn(L)2]·2H2O 45–131131–999 3.98(3.95)
Loss of water of hydration (2H2O)
Decomposition of complex [Zn(L2)]·ZnS + 7C
12 [Fe(HL)2Cl2]Cl·H2O
55–160
160–350
605–700
1.60 (1.80)
70.30(68.80)
8.97(8.45)
Loss of water of hydration (1H2O)
Decomposition of complex and formation
of iron sulfide and carbon
Oxidation of carbon to CO2
[FeCl2(HL)2]Cl
Fe2S3 + 7C
Fe2S3
2.8. Biological Activities
2.8.1. Effect of Ligand 1 and Its Metal Complexes 2, 7 and 9 on Solid Tumor Volume
Mice bearing solid tumors were treated SC with 0.2 mM of ligand 1 and its metal complexes 2, 7
and 9. The treatment was started seven days after EAC implementation in mice and was continued
for 14 consecutive days. Tumor volume was measured after 24 h from the last dose of treatment.
As shown in Table 6, treatment of solid tumor-bearing mice with the ligand 1 resulted in a significant
reduction in tumor volume with inhibition of (36.6%) as compared with tumor-bearing mice treated
with DMSO. Metal complexes 2, 7 and 9 exhibited potent effects on reduction of the volume of solid
tumor. The recorded inhibition percents were 66.5%, 70.37% and 75.53%, respectively, as compared
with tumor-bearing mice treated with the vehicle.
Table 6. Effect of ligand 1 and its metal complexes 2, 7 and 9 on the volume of solid tumor.
Groups Tumor Volume (mm3) Inhibition %
Tumor-bearing mice + DMSO 334.8 ± 17.5 -
Tumor-bearing mice + ligand 1 212.2 ± 22 * 36.6
Tumor-bearing mice + complex 2 112.2 ± 52 ** 66.5
Tumor-bearing mice + complex 7 99.2 ± 17.9 ** 70.37
Tumor-bearing mice + complex 9 82.6 ± 3.9 ** 75.53
Data are presented as mean ± SEM. Significantly (* p < 0.01 and ** p < 0.001) different from mice bearing solid tumor
treated with vehicle (DMSO). -: indicates no value available.
2.8.2. Effect of Ligand 1 and Its Metal Complexes 2, 7 and 9 on the Biochemical Analysis of Serum
As shown in Table 7, EAC cells induced a significant reduction in albumin and glucose and a
significant elevation in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels
(p < 0.001) in comparison with normal mice (normal control group). Conversly, ligand 1 and its metal
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complexes 2, 7 and 9 exhibited significant increase of albumin and glucose levels and decrease ALT
and AST levels relative to tumor-bearing mice treated with DMSO (Table 7).
An increase in glucose catabolism and a decrease in glucose synthesis in the presence of cancer
cells were reported [70,71]. Therefore, the decrease in serum glucose in mice bearing solid tumor
may be due to the tumors exhibit high rate of glycolysis. This is a way of stimulating the body into a
constant state of gluconeogenesis which is accompanied with the reduction in serum albumin [72,73].
Treatment of tumor-bearing mice with ligand 1 and its metal complexes, especially complex 7, restored
serum glucose, albumim, ALT and AST levels towards the standard levels when compared with the
tumor-bearing mice treated with the vehicle.
Table 7. Effect of ligand 1 and its metal complexes 2, 7 and 9 on serum biochemical parameters of mice
bearing solid tumor.
Groups ALT (U/L) AST (U/L) Albumin (g/dL) Glucose (mg/dL)
Normal control 39 ± 3.1 194 ± 35.1 3.3 ± 0.3 128 ± 8.8
Solid tumor + DMSO 77.8 ± 11.5 # 438.6 ± 66.4 # 2.5 ± 0.2 # 80.2 ± 9.5 #
Solid tumor + ligand 1 43.2 ± 9 * 387 ± 45.6 * 2.3 ± 0.3 86.4 ± 11.2
Solid tumor + complex 2 42.2 ± 5 * 275.6 ± 60.9 * 2.4 ± 0.2 122.2 ± 11.6 **
Solid tumor + complex 7 39.2 ± 7.9 * 206.6 ± 54.3 ** 2.5 ± 0.1 126 ± 9.6 ***
Solid tumor + complex 9 36.6 ± 3.9 ** 208 ± 51.2 ** 2.7 ± 0.4 127.4 ± 13.5 **
Data are presented as mean ± SEM. ALT: alanine aminotransferase; AST: aspartate aminotransferase. Significantly
(# p < 0.01) different from the normal mice (untreated) and significantly (* p < 0.05, ** p < 0.01, *** p < 0.001) different
from mice bearing solid tumor treated with vehicle (DMSO).
2.8.3. Effect of Ligand 1 and Its Metal Complexes 2, 7 and 9 on the Expression of Vascular Endothelial
Growth Factor (VEGF) in Tumor and Liver Tissues of EAC Mice
VEGF is a significant angiogenic factor released during the tumor formation to stimulate the
angiogenesis process. Usage of VEGF antagonists is one of the essential anti-angiogenic therapies for
cancer treatment [74]. Therefore, the effect of ligand 1 and its metal complexes 2, 7 and 9 on VEGF
expression was studied in tumor and liver tissues of EAC mice. Results as presented in Figure 2A,B
illustrated that VEGF is highly expressed in tumor and liver tissues of mice bearing solid tumor
compared to normal mice.
The increasing in the VEGF expression level in mice bearing solid tumors was related to the presence
of EAC cells. This finding is consistent with previously reported results which concluded that EAC cells
has been found to exhibit strong VEGF expression level [75]. Moreover, cancer usually enhances VEGF
expression through tumor aggression, therefore, VEGF is involved in cancer pathology [76]. Conversely,
the treatment with ligand 1 and its metal complexes 2, 7 and 9 downregulated the expression of
VEGF in tumor (Figure 2A) and in liver tissues (Figure 2B) of mice bearing solid tumor in comparison
to mice bearing solid tumor treated with DMSO. Complex 9 exhibited the most potent anti-VEGF
activity among the tested compounds. These results revealed that the anti-tumor activities of the tested
compounds might be due to their ability to inhibit VEGF.
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Figure 2. Effect of ligand 1 and its metal complexes 2, 7 and 9 on vascular endothelial growth factor
(VEGF) expression in tumor tissues (A) and in liver tissues (B) of Ehrlich ascites carcinoma (EAC)-bearing
mice. VEGF expression was determined by immunohostochemistry assay. VEGF expression was
expressed as labeling index percentage. Data are expressed as mean ± SEM. Significantly (## p < 0.01)
different from the normal mice and significantly (** p < 0.01) different from mice bearing solid tumor
treated with vehicle (DMSO).
2.8.4. Effect of Ligand 1 and Its Metal Complexes 2, 7 and 9 on the Expression of Cysteine
Aspartyl-Specific Protease-7 (Caspase-7) in Tumor and Liver Tissues of EAC Mice
Apoptosis is a programmed cell death that is caused by caspases that target cysteine aspartyl
residues in target proteins [77]. Defects in apoptosis mechanisms can induce tumor pathogenesis [78],
for example, the activation of caspases by the signal transduction pathway can lead to irreversible
apoptosis through protein degradation [79]. Therefore, it is important to design and develop new
agents that act as caspases activators to treat cancers [80,81]. Consequently, the effect of ligand 1 and
its metal complexe 2, 7 and 9 on the stimulation of caspase-7 was examined in tumor and liver tissues
of EAC mice.
As shown in Figure 3A,B, the induction of solid tumors is associated with low expression of
caspase-7 in tumor and liver tissues of mice bearing solid tumor compared to normal mice. Our finding
was compatible with the reported data demonstrating the declined expression of caspase-3 in mice
bearing EAC cells [82]. On the other hand, the treatment with ligand 1 and its metal complexes 2, 7
and 9 upregulated the expression of caspase-7 in tumor (Figure 3A) and in liver tissues (Figure 3B) of
mice bearing EAC tumor in comparison to mice bearing solid tumor treated with DMSO.
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Complex 9 followed by complex 7 exhibited the most potent apoptotic activity among the tested
compounds. Caspase-7 is a critical mediator of apoptosis and the overexpression of it induced
apoptosis of cancer cells [83]. Therefore, these results revealed that the anti-tumor activities of the
tested compounds might be due to their ability to stimulate caspase-7.
3. Materials and Methods
3.1. Chemistry
3.1.1. Preparation of N(4)-antipyrinylthiosemicarbazide
The preparation of S-methylantipyrine carbodithioate was illustrated in Scheme 1. In details,
4-Aminoantipyrine (40.6 g, 0.2 mol) was added in small portions to an aqueous KOH solution
(11.2 g, 100 mL), and the mixture was maintained below 5 ◦C using ice. Refrigerator-cooled CS2
(11.36 cm3, 0.2 mol) was then added dropwise to the stirred solution over l h while the solution
was maintained below 10 ◦C. To the resulting yellow solution, MeI (11.68 cm3, 0.2 mol) dropwise
was added over 2 h while the temperature was maintained below 10 ◦C. During the addition of
MeI, the yellow colour of the mixture gradually diminished, and a white solid powder was formed.
The crystals of S-methyl-antipyrinecarbodithioate were collected by vacuum filtration and washed
with cold H2O. Because of the noxious odour of this solid (m.p. 193 ± 2 ◦C), it was used immediately
without purification.
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Scheme 1. Preparation of S-methylantipyrine carbodithioate.
The preparation of (4)-antipyrinylthiosemicarbazide was presented in Scheme 2.
S-Methylantipyrinecarbodithioate (29.3 g, 0.1 mol) dissolved in EtOH (30 mL) was added to hydrazine
monohydrate (3.2 mL, 0.1 mol). The solution was heated at reflux until the evolution of methyl
mercaptan was almost complete. The release of methyl mercaptan was detected based on the yellow
colour it imparts to paper moistened with Pb(OAc)2 placed at the mouth of the condenser. The reaction
time for this step was 8 h. The resulting white solid crystals, N(4)-antipyrinyl-thiosemicarbazide, were
collected by vacuum filtration, washed with cold i-PrOH and dried (m.p. 203 ± 2 ◦C).
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3.1.2. Preparation of Isatin N(4)-antipyrine-thiosemicarbazide 1 (ligand)
Isatin N(4)-antipyrine-thiosemicarbazide 1 (ligand) was prepared by mixing equimolar amounts
of isatin and N(4)-antipyrine-thiosemicarbazide in anhydrous EtOH with a few drops of concentrated
H2SO4 at reflux (80 ◦C) for 2 h as shown in Scheme 3.
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metal salt (CuCl2·2H2O, CuBr2, Cu(NO3)2·3H2O, Cu(OAc)2·H2O, Cu(ClO4)2, CoCl2·6H2O, Co(OAc)2·4H2O, 
NiCl2·6H2O, Ni(OAc)2·4H2O, ZnCl2 and FeCl3·6H2O) with the appropriate amount of a hot (75 °C) ethanolic 
solution of the ligand to form a 1:1 L/M (ligand/metal) solution. The reaction mixture was then refluxed for 
approximately 2 h. The obtained precipitates were separated by filtration, washed several times with 
ethanol and then diethyl ether, and then dried under vacuum over anhydrous CaCl2. Due to the poor 
solubility of these complexes in most organic solvents and water, all attempts to prepare a single crystal of 
the ligand or any of the metal complexes were unfortunately unsuccessful. 
[Cu(L)Cl]·H2O (2): Yield (79%), m.p. = 238−240 °C; color: dark brown, ΛM: 10.0 ohm−1 cm2 mol−1, Elemental 
analysis for C20H19N6O3SCuCl., (F.W. = 522.6): Found (calcd) %C 46.0( 46.0), %H 4.1(3.64), %N 16.3( 16.10 ), 
%S 6.88( 6.13): IR (KBr, cm−1), 3395 ν(H2O), 3161, 3100 ν(NH), 1702 ν(C=O)isatin , 1645 ν(C=O)antipyrine , 1616, 
1539 ν(C=N), 808 ν(C=S), 632 ν(Cu-O), 498 ν(Cu-N) UV-Vis. (Nujol mulls) (nm) 310, 325 n→π*, 395, 460, 
525 Charge transfer, 600, 672 , 725 d→d, μeff (B.M) = 1.83. 
[Cu(L)Br]·3H2O (3): Yield (89%), m.p. = 250 °C; color: brown, ΛM: 37.9 ohm−1 cm2 mol−1, Elemental analysis 
for, C20H23N6O5SCuBr, (F.W. = 602.5): Found (calcd) %C 38.81( 39.83), %H 3.54(3.82), %N 15.02(13.94), %S 
5.03(5.31) IR (KBr, cm−1), 3446 ν(H2O), 3106ν(NH), 1695 ν(C=O)isatin, 1643 ν(C=O)antipyrine , 1622 , 1578 ν(C=N), 
806 ν(C=S), 614 ν(Cu-O), 504 ν(Cu-N); UV-Vis. (Nujol mulls) (nm) 325 n→π*, 380, 445, 500 charge transfer, 
580, 631, 660 d→d, μeff (B.M) = 1.81. 
[Cu(L)(NO3)]·H2O (4): Yield (80%), m.p. = 247 °C; color: brown, ΛM: 34.3 ohm−1 cm2 mol−1, Elemental analysis 
for, C20H19N7O6SCu, (F.W. = 548.5): Found (calcd) %C 43.4(43.5), %H 3.29(3.50), %N 18.0(17.9), %S 6.0(5.8); 
IR (KBr, cm−1), 3425ν(H2O), 3166ν(NH), 1703 ν(C=O)isatin, 1645 ν(C=O)antipyrine , 1620, 1539 ν(C=N), 1382 ,1462 
Scheme 3. Preparation of Isatin N(4)-antipyrine-thiosemicarbazide 1 (ligand).
Ligand 1: Yield (87%), m.p. = 210– 12 ◦C; c lor: yellow, Elemental analy is for C20H18N6O2S, (F.W. =
406.): Found (calcd) %C 59.14 (59.00), %H 5.15(4.43), %N 20.91(20.66), %S 7.85(7.87)); IR (KBr, cm−1),
3442, 3348, 3287, 3251, 3141 (NH , 1738 ν(C=O)isatin, 1645 ν(C=O)antipyrine, 1688, 1623, 1595 ν(C=N),
881 ν(C=S ; UV-Vis. (Nujol mulls) (nm) 268, 280, 369 nm, 1H-NMR (MHz, DMSO-d6, δ, ppm): 12.
819 (s, H, thiosemicabazide N-NH), 11.219 (s, 1H, indole N-H), 10.115 (s, 1H, CS-N-H), 7.702–6.876.
(m, multiple, H aromatic protons), .068 (s, 3 H, N-CH3), 2.135 (s, 3 H, CH3). GC–MS: m/z (relative
abundance ; 406 27, 363.47 ( 7.15), 291 (100), 276.68 ( 2.92), 261.69 (28.97), 223.71 (90.05), 204.07 (22.73),
203.3 (26.0), 45.64 (51.57), 130.57 (28.60), 118.18 (78.92), 67.30 (18.68).
3 1 3. Prep ration of the Metal Compl xes
The metal compl xes of the ligand were prepared by mixing a hot ethanolic solution (30 mL)
of the metal salt (CuCl2·2H2O, CuBr2, Cu(NO3)2·3H2O, Cu(OAc)2·H2O, Cu(ClO4)2, Cl2·6H2O,
Co(OAc)2·4H2 , NiCl2·6H2O, Ni(OAc)2·4H2O, ZnCl2 and FeCl3·6H2O) with the appropriate amou t
of a hot (75 ◦C) ethan lic solution of the ligand to form a 1:1 L/M (lig nd/metal) solution. The reaction
mixture was then refluxed for approxima ely 2 h. The obtain precipit es were eparated by filtration,
w shed several tim s with ethanol and then diethyl ether, and then d ied un er vacuum over anhydrous
CaCl2. Due to the poor solubility of these complexe in most organic solvents and water, all attempt to
prepare a single crystal of the ligand or any of the metal complexes were unfortunately unsuccessful.
[Cu(L)Cl]·H2O (2): Yield (79%), m.p. = 238–240 ◦C; color: dark brown, ΛM: 10.0 ohm−1 cm2 mol−1,
Elemental analysis for 20H19N6O3SCuCl., (F.W. = 522.6): Found (calcd) C 46.0(46.0), %H 4.1(3.64),
%N 16.3(16.10), %S 6.88(6.13): IR (KBr, cm−1), 3395 ν(H2O), 3161, 3100 ν(NH), 1702 ν(C=O)isatin, 1645
ν(C=O)antipyrine, 1616, 1539 ν(C=N), 808 ν(C=S), 632 ν(Cu-O), 498 ν(Cu-N) UV-Vis. (Nujol mulls) (nm)
310, 325 n→pi*, 395, 460, 525 Charge transfer, 600, 672, 725 d→d, µeff (B.M) = 1.83.
[Cu(L)Br]·3H2O (3): Yield (89%), m.p. = 250 ◦C; color: brown, ΛM: 37.9 ohm−1 cm2 mol−1, Elemental
analysis for, C20H23N6O5SCuBr, (F.W. = 602.5): Found (calcd) %C 38.81(39.83), %H 3.54(3.82),
%N 15.02(13.94), %S 5.03(5.31) IR (KBr, cm−1), 3446 ν(H2O), 3106ν(NH), 1695 ν(C=O)isatin, 1643
ν(C=O)antipyrine, 1622, 1578 ν(C=N), 806 ν(C=S), 614 ν(Cu-O), 504 ν(Cu-N); UV-Vis. (Nujol mulls)
(nm) 325 n→pi*, 380, 445, 500 charge transfer, 580, 631, 660 d→d, µeff (B.M) = 1.81.
[Cu(L)(NO3)]·H2O (4): Yield (80%), m.p. = 247 ◦C; color: brown, ΛM: 34.3 ohm−1 cm2 mol−1, Elemental
analysis for, C20H19N7O6SCu, (F.W. = 548.5): Found (calcd) %C 43.4(43.5), %H 3.29(3.50), %N 18.0(17.9),
%S 6.0(5.8); IR (KBr, cm−1), 3425ν(H2O), 3166ν(NH), 1703 ν(C=O)isatin, 1645 ν(C=O)antipyrine, 1620,
1539 ν(C=N), 1382,1462 ν(NO3), 808 ν(C=S), 638 ν(Cu-O), 586 ν(Cu-N); UV-Vis. (Nujol mulls) (nm)
310 n→pi*, 390, 455, 520, 574 charge transfer, 675, 720 d→d, µeff (B.M) = 1.78.
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[Cu(L)OAc]·2H2O (5): Yield (74%), m.p. = 212–216 ◦C; color: brown, ΛM: 11.9 ohm−1 cm2 mol−1,
Elemental analysis for, C22H24N6O6SCu, (F.W. = 563.5): Found (calcd) %C 46.12(46.90), %H 4.82(4.30),
%N 15.13 (14.9), %S 5.1(5.7); IR (KBr, cm−1), 3417 ν(H2O), 3237ν(NH), 1680 ν(C=O)isatin, 1645
ν(C=O)antipyrine, 1560, 1525 ν(C=N), 1615, 1333 ν(OAc), 847 ν(C=S), 595 ν(Cu-O), 503 ν(Cu-N); UV-Vis.
(Nujol mulls) (nm) 310 n→pi*, 395, 430, 460, 560 charge transfer, 671,740(br), 870 d→d, µeff (B.M) = 1.79.
[Cu(L)ClO4]·2H2O (6): Yield (91%), m.p. = 250–252 ◦C; color: brown, ΛM: 45.50 ohm−1 cm2 mol−1;
Elemental analysis for, C20H21N6O8SCuCl, (F.W. = 604.5): Found (calcd) %C 38.92(39.70), %H 3.75(3.48),
%N 14.67(13.91), %S 5.18(5.29); IR (KBr, cm−1), 3428 ν(H2O), 3325, 3170ν(NH), 1628 ν(C=O)isatin, 1645
ν(C=O)antipyrine, 1568, 1516ν(C=N), 1118,1085, 694,631 ν(ClO4), 838 ν(C=S), 693 ν(Cu-O), 505 ν(Cu-N);
UV-Vis. (Nujol mulls) (nm) 310 n→pi*, 357, 390, 480(br) charge transfer, 790(br) d→d, µeff (B.M) = 1.76.
[Co(L)Cl]2·2H2O (7): Yield (66%), m.p. = 258–260 ◦C; color: brown, ΛM: 17.9 ohm−1 cm2 mol−1,
Elemental analysis for C40H38N12O6S2Co2Cl2, (F.W. = 1034.8): Found (calcd) %C 47.0(46.38), %H
4.17(3.7), %N 17.0(16.21), %S .4(6.18), IR (KBr, cm−1), 3388 ν(H2O), 3150 ν(NH), 1734 ν(C=O)isatin, 1645
ν(C=O)antipyrine, 1600, 1515 ν(C=N), 841 ν(C=S), 585 ν(Co-N); GC–MS: m/z (relative abundance); 999.5
(22.46), 869.45 (15.13), 464.94 (4.00); UV-vis. (Nujol mulls) (nm) 318, 345 n→pi*, 390, 450(br) charge
transfer, 600, 675, 700 d→d, µeff (B.M) = 3.1.
[Co(L)OAc(H2O)]·4H2O (8): Yield (75%), m.p. > 300 ◦C; color: brown, ΛM: 4.6 ohm−1 cm2 mol−1,
Elemental analysis for C22H30N6O9SCo, (F.W. = 612.5): Found (calcd) %C 42.96(43.10), %H 5.3(4.89),%N
14.20(13.71), %S 4.87(5.22); IR (KBr, cm−1), 3491, 3422 ν(H2O), 3196ν(NH), 1734 ν(C=O)isatin, 1645
ν(C=O)antipyrine, 1590, 1545 ν(C=N), 1619, 1372 ν(OAc), 841 ν(C=S), 540 ν(Co-N); GC–MS: m/z (relative
abundance); 612.85 (100), 576.23 (94.07, 561.30 (61.93), 541.85 (6.86), 523.22 (39.20); UV-Vis. (Nujol
mulls) (nm) 320 n→pi*, 390, 440(br), 530(br) charge transfer, 600, 675, 780d→d, µeff (B.M) = 3.7
[Ni(HL)2Cl2]·4H2O (9): Yield (84%), m.p. = 254–255 ◦C; color: brown, ΛM: 13.5 ohm−1 cm2 mol−1,
Elemental analysis for C40H44N12O8S2 NiCl2., (F.W. = 1014.9): Found (calcd) %C 46.84(47.3), %H
4.94(4.33), %N 16.95(16.55), %S 5.89(6.30); IR (KBr, cm−1), 3441 ν(H2O), 3280 ν(NH), 1735, 1660
ν(C=O)isatin, 1645, 1620 ν(C=O)antipyrine, 1595(sh), 1520(sh) ν(C=N), 880 ν(C=S), 648 ν(Ni-O), 591
ν(Ni-N); UV-VIS. (Nujol mulls) (nm) 320 n→pi*, 396, 420, 530 charge transfer, 560(s), 690(w), 950(br)
d→d, µeff (B.M) = 2.98.
[Ni(L)OAc]2·4H2O (10): Yield (70%), m.p. > 300 ◦C; color: brown,ΛM: 2.60 ohm−1 cm2 mol−1, Elemental
analysis for C44H48N12O12S2 Ni2, (F.W. = 1017.4): Found (calcd) %C 47.76(47.24), %H 4.19(4.3), %N,
15. 60(15.03), %S 6.71(5.78); IR (KBr, cm−1), 3445 ν(H2O), 3310, 3200 ν(NH), 1664 ν(C=O)isatin, 1620
ν(C=O)antipyrine, 1580, 1540 ν(C=N), 1620, 1342 ν(OAc), 829 ν(C=S), 590 ν(Ni-O), 503 ν(Ni-N); UV-Vis.
(Nujol mulls) (nm) 305, 315 n→pi, 395, 450, 530 charge transfer, 567(s), 670(sh). 950(br) d→d, µeff (B.M)
= 3.06.
[Zn(L)2]·2H2O (11): Yield (69%), m.p. > 300 ◦C; color: dark yellow, ΛM: 1.40 ohm−1 cm2 mol−1,
Elemental analysis for C40H38N12O6S2 Zn, (F.W. = 911.50): Found (calcd) %C 51.9(52.6), %H 3.7
(4.2), %N 18.8 (18.42), %S 6.64 (7.0); IR (KBr, cm−1 3413 ν(H2O), 3223ν(NH), 1700 ν(C=O)isatin, 1643
ν(C=O)antipyrine, 1609, 1570 ν(C=N), 815 ν(C=S), 612 ν(Zn-O), 580 ν(Zn-N): 1H-NMR (MHz, DMSO-d6,
δ, ppm): 11.22 (s, 1H, indole N-H), 11.008 (s,1H, CS-N-H), 7.704–6.879. (m, multiple, C-H aromatic),
3.111 (s, 3 H, N-CH3), 2.174 (s, 3 H, CH3); GC–MS: m/z (relative abundance); 911.5 (1.19) UV-Vis. (Nujol
mulls) (nm) 319 n→pi, 396, 440, 491, 520(sh).
[Fe(HL)2Cl2]Cl·H2O (12): Yield (78%), m.p. = 210–212 ◦C; color: dark green, ΛM: 74.50 ohm−1 cm2 mol−1,
Elemental analysis for C40H38N12O5S2FeCl3, (F.W. = 992.50): Found (calcd) %C 47.62(48.3), %H 3.9(3.8),
%N 16.95 (16.91), %S 5.6 (6.44), IR (KBr, cm−1), 3429(s,br) ν(H2O), 3280 ν(NH), 1737, 1700 ν(C=O)isatin,
1645, 1621 ν(C=O)antipyrine, 1610, 1576 ν(C=N), 880 ν(C=S), 589 ν (Fe-O), 512 ν(Fe-N) GC–MS: m/z
(relative abundance); 992.5 (11.39), 974.50 (1.90), 938.30 (12.96), 869.80 (8.27), 464.40 (2.48); UV-Vis. (Nujol
mulls) (nm) 300, 340 n→pi, 391, 450, 530(sh) charge transfer, 567(s), 584 d→d, µeff (B.M) = 5.95.
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3.1.4. Instrumentation and Measurements
Elemental microanalyses [C, H, and N] were conducted in the Micro Analytical Unit. The IR
spectra were acquired using KBr discs in a Spirit model FT-IR spectrophotometer (Shimadzu, Thermo
Scientific, Glasgow, UK). The 1H-NMR spectra of the ligand and zinc complex were recorded in
DMSO-d6 on a Gemini 200 NMR spectrophotometer (Varian, Palo Alto, CA, USA) at 300 MHz. Mass
spectra were collected using a model ISQLT direct probe controller with a single quadrupole mass
analyser (Thermo Scientific, Glasgow, UK) using Thermo X-calibur software (Xcalibur 4.1). Solid-state
electronic spectra were recorded in Nujol mulls using a Shimadzu UV-Vis 1800 spectrophotometer
(Thermo Scientific, Glasgow, UK). The molar conductance of a 1 × 10−3 M solution of the complexes
in N,N-dimethylformamide (DMF) was measured at 25 ◦C with a Bibby MCl-type conductometer
(Chelmsford, UK). The resistance was measured in ohms and the molar conductivities were calculated
according to the following equation: ΛM = VxKxg/Mw* Ω where ΛM = molar conductivity
(Ω-1cm2mol-1), V = volume of the complex solution (mL), K = cell constant (0.92 cm-1), Mw = molecular
weight of the complex, g = weight of the complex (g), and Ω = resistance (Ω).
The solid-state electron paramagnetic resonance (EPR) spectra of the copper(II) complexes were
recorded with an X-band EMX spectrometer (Bruker, Berlin, Germany) using a standard rectangular
cavity of ER 4102 operating at 9.5 GHz with 100 kHz modulation at 298 K. Diphenyl picryl hydrazide
(DPPH) was used as a g-marker to calibrate the spectra. The thermal analyses (TGA) were carried out
in air using a Shimadzu DT-30 thermal analyser. Magnetic susceptibilities were measured at 27 ◦C
using the modified Gouy method with a Johnson Matthey balance and were calculated using the
following equation:
Me f f = 2.84
√
xcorrm ·T
3.2. Biological Evalution
3.2.1. Preparation of Solutions of the Complexes
Stock solutions (1 mM) of the newly synthesized complexes were prepared by dissolving each
complex in dimethylsulfoxide (DMSO)/H2O, and the solutions were stored at 4 ◦C. Only ligand 1 and
complexes 2, 7 and 9 were successfully solubilized, allowing their antitumor activities to be determined.
3.2.2. Experimental Animals
Adult female Swiss albino mice (6–7 weeks old), weighing 20–22 g, were purchased and housed
under standard ventilation and light cycle conditions. They were given food and water ad libitum.
The current study protocol was approved by the Ethical Committee for Laboratory Animals of Science
Faculty Menoufia University (No.: ECLA-SFMU-18015).
3.2.3. Tumor Cell Line
The Ehrlich ascites carcinoma (EAC) cell line was purchased from the National Cancer Institute
(NCI, Cairo, Egypt). The EAC cell line was maintained in the peritoneal cavity of adult female Swiss
albino mice by serial intraperitoneal transplantation of 2.5 × 106 cells weekly.
3.2.4. Induction of Solid Tumor and Animals Grouping
The solid tumor was induced by subcutaneously (SC) injecting 1 × 10−6 EAC cells into the right
thigh of the lower limb of mice [84,85]. Seven days after tumor inoculation, the tumor volume became
palpable. The mice were randomly divided in separate cages into six groups:
Group 1 (normal control): mice without any treatment.
Group 2 (vehicle group): mice bearing solid tumors treated with DMSO/H2O.
Group 3: mice bearing solid tumor and treated subcutaneously with 0.2 mM of ligand 1.
Group 4: mice bearing solid tumor and treated subcutaneously with 0.2 mM of complexe 2.
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Group 5: mice bearing solid tumor and treated subcutaneously with 0.2 mM of complexe 7.
Group 6: mice bearing solid tumor and treated subcutaneously with 0.2 mM of complexe 9.
The doses were selected based on the LD50 values of the complexes (data not shown). The treatment
was started seven days after EAC implementation and was continued for 14 consecutive days.
3.2.5. Blood and Tissue Samples Collection
At the end of the experiment, mice were sacrificed. Blood samples were collected from jugular
vein puncture into chilled non-heparinized tubes, which were centrifuged at 40× g for 10 min at 4 ◦C.
The sera were frozen at−20 ◦C for future measurements. The livers and solid tumors were removed and
cut into pieces, and the individual pieces were fixed in paraffin blocks for immunohistochemical assays.
3.2.6. Assessment of Tumor Volume (TV)
After 24 h from the last dose of treatment, mice were sacrificed and the solid tumors were carefully
removed. The volume of the tumors was assessed [86] using the following formula: TV (mm3) = 4pi
(A/2)2 × (B/2), where (A) is the minor tumor axis and (B) is the major tumor axis.
3.2.7. Biochemical Analysis of the Serum
To determine the effect of ligand 1 and its metal complexes 2, 7 and 9 on the serum biochemical
profile. The levels of alanine transaminase (ALT), aspartate transaminase (AST), albumin and glucose
were determined using a Beckman autoanalyzer apparatus, Brea, CA, USA).
3.2.8. Immunohistochemical Examination of VEGF and Caspase-7 in Solid Tumors and Liver Tissues
The effect of ligand 1 and its metal complexes 2, 7 and 9 on the expression of VEGF and
caspase-7 in solid tumor tissues and in liver tissues of mice bearing solid tumors was deremined by
immunohistochemical methods. In details, the sections of tumor and liver tissues in paraffin were
dewaxed, hydrated, and immersed in antigen retrieval solution (EDTA solution, pH 8). The samples
were treated with 0.3% hydrogen peroxide and protein block and then incubated with anti-VEGF
(Santa Cruz, Dallas, TX, USA, 1:100 dilution) and anti-caspase-7 (Lab Vision, Thermo Fischer Scientific,
Glasgow, UK; ready to use) at 4 ◦C overnight. The slides were rinsed three times with PBS and
incubated with anti-mouse IgG secondary antibodies (EnVision + System HRP; Dako, SanJose, CA,
USA) for 30 min at room temperature. The samples were visualized with diaminobenzidine commercial
kits (Liquid DAB+Substrate Chromogen System; Dako) and finally counterstained with Mayer’s
haematoxylin. In the negative control, the primary antibody was replaced with normal mouse serum.
The positive cells were counted from seven high-power fields of 400×. The labelling index (%) was
determined by dividing the number of positive cells by the total cells × 100 [87,88].
3.3. Statistical Analysis
Data are expressed as mean ± SEM and the statistical comparison between groups were analyzed
using one-way ANOVA followed by Tukey post hoc test. A p of < 0.05 value was considered
statistically significant.
4. Conclusions
In summary, new metal complexes derived from isatin-N-(4)antipyrinethiosemicarbazone ligand
1 were synthesized and characterized. Also, their potential anti-cancer activities against solid tumors
induced by EAC cells in mice were investigated. The results revealed that the tested complexes
significantly reduced the volume of solid tumors. This reduction was associated with an increase in
the level of caspase-7 and a dramatic decrease in the VEGF level. The tested complexes are promising
anti-cancer agents those exert their activities via the induction of apoptosis and the inhibition of
angiogenesis, leading to reduction of the tumor size.
Molecules 2019, 24, 3313 21 of 25
Supplementary Materials: The following are available online; 1H-NMR, Mass, IR, EPR, TGA, and
UV-Visible spectra.
Author Contributions: Conceptualization, F.E.-S., B.E.-A. and T.S.; Formal analysis, B.E.-A. and F.E.-S.;
Funding acquisition, S.A.M.K. and H.R.E.-S.; Methodology, B.E.-A., and G.S.; Visualization, B.E.-A. and F.E.-S.;
Writing—original draft, B.E.-A., F.E.-S., and G.S.; Writing—review & editing, B.E.-A., G.S., S.A.M.K., and H.R.E.-S.
All authors have read and approved the manuscript.
Funding: We are very grateful to the Swedish Research links grant 2016-05885 (VR for the years 2017–2019) for
generious financial support.
Acknowledgments: H.R.E.-S. is very grateful to Jiangsu University, China for Foreign Expert fellowship.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA 2019, 69, 7–34. [CrossRef] [PubMed]
2. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1, 27–30.
[CrossRef] [PubMed]
3. Thapa, D.; Lee, J.S.; Heo, S.W.; Lee, Y.R.; Kang, K.W.; Kwak, M.K. Novel hexahydrocannabinol analogs as
potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis. Eur. J. Pharmacol. 2011, 650,
61–71. [CrossRef] [PubMed]
4. El-Aarag, B.Y.; Kasai, T.; Zahran, M.A.; Zakhary, N.I.; Shigehiro, T.; Sekhar, S.C.; Agwa, H.S.; Mizutani, A.;
Murakami, H.; Kakuta, H.; et al. In vitro anti-proliferative and anti-angiogenic activities of thalidomide
dithiocarbamate analogs. Int. Immunopharmacol. 2014, 21, 283–292. [CrossRef] [PubMed]
5. El-Aarag, B.; Kasai, T.; Masuda, J.; Zahran, M.; Agwa, H.; Seno, M. Anticancer effects of novel thalidomide
analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2.
Biomed. Pharmacother. 2017, 85, 549–555. [CrossRef] [PubMed]
6. Zahran, M.; Agwa, H.; Osman, A.; Hammad, S.; El-Aarag, B.; Ismail, N.; Salem, T.; Gamal-Eldeen, A. Synthesis
and biological evaluation of phthalimide dithiocarbamate and dithioate derivatives as anti-proliferative and
anti-angiogenic agents-I. Eur. J. Chem. 2017, 8, 391–399. [CrossRef]
7. Kamal, A.; Kumar, G.B.; Nayak, V.L.; Reddy, V.S.; Shaik, A.B.; Reddy, M.K. Design, synthesis and biological
evaluation of imidazopyridine/imidazopyrimidine-benzimidazole conjugates as potential anticancer agents.
Med. Chem. Commun. 2015, 6, 606–612. [CrossRef]
8. Yang, L.L.; Lee, C.Y.; Yen, K.Y. Induction of apoptosis by hydrolyzable tannins from Eugenia jambos L. on
human leukemia cells. Cancer Lett. 2000, 157, 65–75. [CrossRef]
9. Rosu, T.; Negoiu, M.; Pasculescu, S.; Pahontu, E.; Poirier, D.; Gulea, A. Metal-based biologically active agents:
Synthesis, characterization, antibacterial and antileukemia activity evaluation of Cu(II), V(IV) and Ni(II)
complexes with antipyrine-derived compounds. Eur. J. Med. Chem. 2009, 45, 774–781. [CrossRef]
10. Leovac, V.M.; Bogdanovic, G.A.; Jovanovic, L.S.; Joksovic, L.C.; Markovic, I.; Joksovic, M.D. Synthesis,
characterization and antitumor activity of polymeric copper(II) complexes with thiosemicarbazones of
3-methyl-5-oxo-1-phenyl-3-pyrazolin-4-carboxaldehyde and 5-oxo-3-phenyl-3-pyrazolin-4-carboxaldehyde.
J. Inorg. Biochem. 2011, 105, 1413–1421. [CrossRef] [PubMed]
11. Refata, M.S.; El-Metwaly, N.M. El-Metwaly, Spectral, thermal and biological studies of Mn(II) and Cu(II)
complexes with two thiosemicarbazide derivatives. Spectrochim. Acta Part A 2012, 92, 336–346. [CrossRef]
[PubMed]
12. Mendes, I.C.; Moreira, J.P.; Mangrich, A.S.; Balena, S.P.; Rodrigues, B.L.; Beraldo, H. Coordination to copper
(II) strongly enhances the in vitro antimicrobial activity of pyridine-derived N(4)-tolyl thiosemicarbazones.
Polyhedron 2007, 26, 3263–3270. [CrossRef]
13. Vinuelas-Zahinos, E.; Maldonado-Rogado, M.A.; Luna-Giles, F.; Barros-Garcia, F.J. Coordination behaviour
of Schiff base 2-acetyl-2-thiazoline hydrazone (ATH) towards cobalt(II), nickel(II) and copper(II). Polyhedron
2008, 27, 879–886. [CrossRef]
14. Bharti, N.; Shailendra, Y.; Sharma, S.; Naqvi, F.; Azam, A. New palladium(II) complexes of
5-nitrothiophene-2-carboxaldehyde thiosemicarbazones. synthesis, spectral studies and in vitro anti-amoebic
activity. Bioorg. Med. Chem. 2003, 11, 2923–2929. [CrossRef]
Molecules 2019, 24, 3313 22 of 25
15. El-Sawaf, A.K.; West, D.X.; El-Saied, F.A.; El-Bahnasawy, R.M. Synthesis, magnetic and spectral
studies of iron(III), cobalt(II,III), nickel(II), copper(II) and zinc(II) complexes of 4–formylantipyrine
N(4)-antipyrinylthiosemicarbazone. Transit. Met. Chem. 1998, 23, 649–655. [CrossRef]
16. El-Sawaf, A.K.; West, D.X.; El-Saied, F.A.; El-Bahnasawy, R.M. Copper(II) complexes of 4-formylantipyrine
N(4)-substitutedthiosemicarbazones. Transit. Met. Chem. 1998, 22, 360–365. [CrossRef]
17. Ali, A.Q.; Teoh, S.G.; Salhin, A.; Eltayeb, N.E.; Ahamed, M.B.K.; Majid, A.A. Synthesis of isatin
thiosemicarbazones derivatives: In vitro anti-cancer, DNA binding and cleavage activities. Spectrochim. Acta A
2014, 125, 440–448. [CrossRef] [PubMed]
18. El-Saied, F.A.; El-Enein, S.A.A.; Emam, S.M.; El-Shater, H.A. Synthesis and characterization of Cu(II),
Ni(II), Co(II), Mn(II), Zn(II), Ru(III), Hf(IV) and ZrO(II) complexes of 2-thiophenylidene-N-4-methoxy
anilinoacetohydrazone. Polish J. Chem. 2009, 83, 1871–1883.
19. Detrov, I.; Grupce, O.; Stafilov, T. The N-H stretching region of some imides and thioimides. Mol. Struct.
1986, 142, 275–278.
20. Castineiras, A.; Gomez, M.C.; Sevillano, P. 2-(2,3-Dihydro-1,3-benzothiazol-2-yl)phenyl(diphenyl) phosphine
oxide, Synthesis and characterization by IR and NMR spectroscopy and X-ray diffractometry. Mol. Struct.
2000, 554, 301–306. [CrossRef]
21. Prasad, R.N.; Mathur, M.; Upadhayay, A. Synthesis and spectroscopic studies of Cr (III), Fe (III) and Co (II)
complexes of hexaazamacrocycles. Indian Chem. Soc. 2007, 84, 1202–1204.
22. Husain, K.; Bhat, A.; Azam, A. New Pd(II) complexes of the synthesized 1-N-substituted thiosemicarbazones
of 3-indole carboxaldehyde: Characterization and antiamoebic assessment against E. histolytica. J. Med. Chem.
2008, 43, 2016–2028. [CrossRef] [PubMed]
23. Mikuriya, M.; Okawa, H.; Kida, S. Binuclear Metal Complexes. XXXV. Synthesis and Magnetism of Binuclear
Copper(II) Complexes with 3-[2-(Dialkylamino)ethylthio]-1-propanols. Bull. Chem. Soc. 1980, 53, 3717–3718.
[CrossRef]
24. Rreti, C.; Tosr, G. Complexes of Co alt (II), Nickel (II) and Copper Acetates, Perchlorates, and Tetrafluoroborates
with Heterocyclic Ligands Containing VA and VIA group Donor Atoms. Can. J. chem. 1975, 53, 177–182.
25. Jain, S.K.; Garg, B.S.; Bhoon, Y.K. Iron(III) complexes of 2-acetylpyridine-4-phenyl-3-thiosemicarbazones:
Magnetic, E.s.r. and spectral studies. Transit. Met. Chem. 1986, 11, 89–95. [CrossRef]
26. Maurya, R.C.; Rajput, S. Neutral dioxovanadium(V) complexes of biomimetic hydrazones ONO donor ligands
of bioinorganic and medicinal relevance: Synthesis via air oxidation of bis(acetylaceto-nato)oxovanadium(IV),
characterization, biological activity and 3D molecular modeling. J. Mol. Struct. 2007, 833, 133–144. [CrossRef]
27. Sallam, S.A.; Orabi, A.S.; El-Shetary, B.A.; Lentz, A. Copper, nickel and cobalt complexes of Schiff-bases
derived from β-diketones. Transit. Met. Chem. 2002, 27, 447–453. [CrossRef]
28. Tossidis, A.; Bolos, C.A. Monohalogenobenzoylhydrazones II. Synthesis and Study of Ti(IV) Complexes
with Monochlorobenzoylhydrazones of 2-Furaldehyde, 2-Thiophenaldehyde, 2-Pyrrolaldehyde and
Di-2-pyridylketone as Ligands. Inorg. Chim. Acta 1986, 112, 93–97. [CrossRef]
29. Ainscough, E.W.; Brodie, A.M.; Dobbs, A.J.; Ranford, J.D.; Waters, J.M. Antitumour copper(II)
salicylaldehyde benzoylhydrazone (H2sb) complexes: Physicochemical properties and the single-crystal X-ray
structures of [{Cu(H2sb)(CCl3CO2)2}2] and [{Cu(Hsb) (ClO4) (C2H5OH)}2] and the related salicylaldehyde
acetylhydrazone (H2sa) complex, [Cu(Hsa)Cl(H2O)]·H2O. Inorg. Chim. Acta 1998, 267, 27–38.
30. El-Sawaf, A.K.; Nassar, A.A.; El-Samanody, E. Synthesis, magnetic, spectral and biological studies of copper
(II) complexes of 4-benzoyl-3-methyl-1-phenyl-2-pyrazolin-5-one N(4)-substituted thiosemicarbazones.
Sci. J. Chem. 2014, 2, 17–26. [CrossRef]
31. Nair, M.K.M.; Radhakrishnan, P.K. Iodide Complexes of Yttrium and Lanthanides with
4-N-(4′-Antipyrylmethylidene) aminoantipyrine. Synth. React. Inorg. Met. Org. Chem. 1996, 26,
529–541. [CrossRef]
32. Afrasiabi, Z.; Sinn, E.; Padhye, S.; Dutta, S.; Padhye, S.; Newton, C.; Anson, C.E.; Powell, A.K. Transition
metal complexes of phenanthrenequinone thiosemicarbazone as potential anticancer agents: Synthesis,
structure, spectroscopy, electrochemistry and in vitro anticancer activity against human breast cancer cellline,
T47D. J. Inorg. Biochem. 2003, 95, 306–314. [CrossRef]
33. Fouda, M.F.R.; Abd-Elzaher, M.M.; Shakdofa, M.M.; El-Saied, F.A.; Ayad, M.I.; el Tabl, A.S. Synthesis
and Characterization of a Hydrazone Ligand Containing Antipyrine and its Transition Metal Complexes.
J. Coord. Chem. 2008, 61, 1983–1996. [CrossRef]
Molecules 2019, 24, 3313 23 of 25
34. Lever, A.B.P. Electronic Spectra of Some Transition Metal Complexes: Derivation of Dq and B. J. Chem. Educ.
1968, 45, 711–712. [CrossRef]
35. Shebl, M.; El-ghamry, M.A.; Khalil, S.M.; kishk, M.A. Mono- and binuclear copper(II) complexes of new
hydrazone ligands derived from 4,6-diacetylresorcinol: Synthesis, spectral studies and antimicrobial activity.
Spectrochim. Acta A Mol. Biomol. Spectrosc. 2014, 21, 232–241. [CrossRef] [PubMed]
36. Downes, J.M.; Whelan, J.; Bosnich, B. Biological analogs, Spectroscopic characteristics of mercapto- and
disulfide-copper(II) coordination in relation to type I proteins. Inorg. Chem. 1981, 20, 1081–1086. [CrossRef]
37. Okawa, H.; Nakamoto, M.; Lzumitani, T.; Kida, S. Syntheses and Configurations of Copper(II) and Nickel(II)
Complexes of trans-1,2-Dicyano-1,2-cyclohexanediamine. Bull. Chem. Soc. 1982, 55, 2671–2672. [CrossRef]
38. Suzuki, M.; Kanatomi, H.; Koyama, H.; Murase, I. Copper(I) and Copper(II) Complexes of Tripod Ligands,
Tris(2-alkylthioethyl)amine. Bull. Chem. Soc. 1980, 53, 1961–1964. [CrossRef]
39. Kovala-Dermertzi, D.; Tsangaris, J.M.; Hadjiliadis, N. Complexes of aminobenzylamines. Part I. Complexes
of O-aminobenzylamine with copper(II), cobalt(II) and nickel(II). Transit. Met. Chem. 1983, 8, 140–146.
[CrossRef]
40. Suzuki, M.; Demura, H.K.Y.; Murase, I. Syntheses and Properties of Dinuclear Copper(II) Complexes with
2,6-Bis[bis(2-pyridylmethyl)aminomethyl]-4-methylphenol. Bull. Chem. Soc. 1984, 57, 1003–1007. [CrossRef]
41. El-Tabl, A.S.; El-Bahnasawy, R.M.; Hamdy, A.E.D. Synthesis, magnetic, spectral and antimicrobial studies on
metal complexes of 4- methylphenylaminoacetoisatin hydrazine. J. Chem. Res. 2009, 11, 659–664.
42. Chohan, Z.H.; Pervez, H.; Khan, K.M.; Supuran, C.T. Metal binding and antibacterial activity of ciprofloxacin
complexes. J. Enzym. Inhib. Med. Chem. 2005, 20, 303–307. [CrossRef] [PubMed]
43. Lever, A.B.P. Inorganic Electronic Spectroscopy, Studies in Physical and Theoretical Chemistry; Elsevier Science
Ltd.: Amsterdam, The Netherlands, 1984.
44. Matovic, Z.D.; Miletic, V.D.; Samardzic, G.; Pelosi, G.; Ianelli, S.; Trifunovic, S. Square-planar copper(II)
complexes with a tetradentate amido-carboxylate ligands. Crystal structure of Na2[Cu(obap)]2·2H2O. Strain
analysis and spectral assignments of complexes. Inorg. Chim. Acta 2005, 358, 3135–3144. [CrossRef]
45. Mangalam, N.A.; Kurup, M.R.P. Versatile binding properties of a di-2-pyridyl ketone nicotinoylhydrazone
ligand: Crystal structure of a Cu(II) complex. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2011, 78,
926–934. [CrossRef] [PubMed]
46. Aly, M.M.; Imam, S.M. Characterization of Copper(II), nickel(II), cobalt(II) and palladium(II) complexes
of vicinal oxime-imine ligands; induced chelate isomerism in the same molecule of the nickel(II) complex.
Mon. Chem. Chem. Mon. 1995, 126, 173–185. [CrossRef]
47. el Saied, F.A.; Shakdofa, M.M.E.; el Tabl, A.S.; Elzaher, M.M.A. Coordination behaviour of N′1,N′4-bis((1,
5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)methylene) succinohydrazide toward transition
metal ions and their antimicrobial activities. Main Group Chem. 2014, 13, 87–99.
48. Pahont,u, E.; Ilies, , D.C.; Shova, S.; Oprean, C.; Păunescu, V.; Olaru, O.T.; Rădulescu, F.S, .; Gulea, A.; Ros, u, T.;
Drăgănescu, D. Synthesis, Characterization, Antimicrobial and Antiproliferative Activity Evaluation of
Cu(II), Co(II), Zn(II), Ni(II) and Pt(II) Complexes with Isoniazid-Derived Compound. Molecules 2017, 22, 650.
49. Earnshaw, A. Introduction to Magneto-Chemistry; Academic Press: New York, NY, USA, 1968.
50. Chandra, S.; Sharma, K.K. Cobalt(II) and nickel(II) complexes of some nitrogen-oxygen and nitrogen-sulphur
ligands. Transit. Met. Chem. 1984, 9, 1–3. [CrossRef]
51. El-Tabl, A.S.; El-Saied, F.A.; Al-Hakimi, A.N. Synthesis, spectroscopic investigation and biological activity of
metal complexes with ONO trifunctionalalized hydrazone ligand. Transit. Met. Chem. 2007, 32, 689–701.
[CrossRef]
52. Fouda, M.F.R.; Abd-El-zaher, M.M.; Shakdofa, M.M.; El-Saied, F.A.; Ayad, M.I.; El-Tabl, A.S.
Synthesis and characterization of transition metal complexes of N′-[(1, 5-dimethyl-3-oxo-2-phenyl-2,
3-dihydro-1H-pyrazol-4-yl) methylene] thiophene-2-carbohydrazide. Transit. Met. Chem. 2008, 33, 219–228.
[CrossRef]
53. Al-Tabl, A.S.; AbouEl-Enein, S.A. Reactivity of the new potentially binucleating ligand, 2-(acetichydrazido-
N-methylidene-α-naphthol)-benzothiazol, towards manganese (II), nickel (II), cobalt (II), copper (II) and zinc
(II) salts. J. Coord. Chem 2004, 57, 281–294. [CrossRef]
54. El-Reash, G.M.A.; Ibrahim, K.M.; Bekheit, M.M. Structural studies of 4(phenyl or benzamidos)-1-cyclohexa-
none-3- thiosemicarbazone complexes. Transit. Met. Chem. 1990, 15, 148–151.
Molecules 2019, 24, 3313 24 of 25
55. El-Saied, F.A.; El-Asmy, A.A.; Kaminsky, W.; West, D.X. Spectral and structural studies of cobalt(II,III),
nickel(II), and copper(II) complexes of dehydroacetic acid N4-dialkyl- and 3-azacyclothiosemicarbazones.
Transit. Met. Chem. 2003, 28, 954–960. [CrossRef]
56. El-Tabl, A.S.; Shakdofa, M.M.E.; El-Seidy, A.M.A.; Al-Hakimi, A.N. Synthesis, characterization
and antifungal activity of metal complexes of 2-(5-((2-chlorophenyl) diazenyl)-2-hydroxybenzylidene)
hydrazinecarbothioamide. Phosphorus Sulfur Silicon Relat. Elem. 2012, 187, 1312–1323. [CrossRef]
57. Kasumov, V.T.; Köksal, F. Synthesis, ESR, UV-Visible and reactivity studies of new bis(N-dimethoxyaniline-
3,5-(t)Bu2-salicylaldiminato)copper(II) complexes. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2012, 98,
207–214. [CrossRef] [PubMed]
58. Hathaway, B.J.; Billing, D.E. The electronic properties and stereochemistry of mono-nuclear complexes of the
copper(II) ion. Coord. Chem. Rev. 1970, 5, 1949. [CrossRef]
59. Zaky, R.R.; Ibrahim, K.M.; Gabr, I.M. Bivalent transition metal complexes of o-hydroxyacetophenone
[N-(3-hydroxy-2-naphthoyl)] hydrazone: Spectroscopic, antibacterial, antifungal activity and
thermogravimetric studies. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2011, 81, 28–34. [CrossRef]
[PubMed]
60. Brown, D.R.; West, D.X. An ESR study of addition species formed between bis(2-thiopyridine N-oxide)Cu(II)
and heterocyclic and aliphatic amines. J. Inorg. Nucl. Chem. 1981, 43, 1017–1021. [CrossRef]
61. Nagashri, K.; Joseph, J.; Dhanaraj, C.J. Copper (II) complexes of hydroxyflavone derivatives as potential
bioactive molecule to combat antioxidants: Synthesis, characterization and pharmacological activities.
Appl. Organomet. Chem. 2011, 25, 704–717. [CrossRef]
62. Proctor, I.M.; Hathaway, B.J.; Nicholis, P. The electronic properties and stereochemistry of the copper(II) ion.
Part I. Bis(ethylenediamine)copper(II) complexes. J. Chem. Soc. A 1968, 1678–1684. [CrossRef]
63. Kivelson, D.; Neiman, R. ESR Studies on the Bonding in Copper Complexes. J. Chem. Phys. 2004, 35, 149.
[CrossRef]
64. Shauib, N.M.; Elassar, A.Z.A.; El-Dissouky, A. Synthesis and spectroscopic characterization of copper(II)
complexes with the polydentate chelating ligand 4,4’-[1,4-phenylenedi(nitrilo)dipente-2-one. Spectrochim.Acta
Part A Mol. Biomol. Spectrosc. 2006, 63, 714–722. [CrossRef] [PubMed]
65. Ray, R.K.; Kauffmann, G.B. An EPR study of copper(II)-substituted biguanide complexes. Part III.
Inorg. Chim. Acta 1990, 174, 237–244. [CrossRef]
66. Hathaway, B.J. A new look at the stereochemistry and electronic properties of complexes of the copper(II)
ion. Complex Chem. 1984, 57, 55–118.
67. Sakaguchi, U.; Adison, A.W. Spectroscopic and redox studies of some copper(II) complexes with biomimetic
donor atoms: Implications for protein copper centres. J. Chem. Soc. Dalton Trans. 1979, 4, 600–608. [CrossRef]
68. El-Tabl, A.S. Synthesis and spectral studies on mononuclear copper (II) complexes of isonitrosoacetylacetone
ligand. Polish J. Chem. 1997, 71, 1213–1222.
69. Mahajian, M.; Saxena, K.N.; Saxen, P.C. ESR study of Cu(II) complexes. Inorg. Nucl.Chem. 1981, 43, 2148–2149.
[CrossRef]
70. Oscar, C. Biopharmacological studies on certain new anticancer drugs. J. Biochem. 1988, 110, 701–707.
71. Tagmizyan, W.A. Metabolism of impaired glucose in patients with neoplasia. Am. Biol. 1990, 2, 53–58.
72. Silverstein, H.; Dervot, K.; Oscar, D. Studies on carbohydrate metabolism and different types of tumors
bearing animals. Lancet 1988, 22, 40–45.
73. Kind, P.R.N.; Gordon, M.; Laverick, M.; Nias, A.H.; Slavin, B.M. The effect of C3H mouse mammary tumor
on the levels of serum and urine analytes in vivo. Br. J. Cancer 1985, 52, 607–612. [CrossRef] [PubMed]
74. Parveen, A.; Subedi, L.; Kim, H.W.; Khan, Z.; Zahra, Z.; Farooqi, M.Q.; Kim, S.Y. Phytochemicals Targeting
VEGF and VEGF-Related Multifactors as Anticancer Therapy. J. Clin. Med. 2019, 8, 350. [CrossRef] [PubMed]
75. Abd-Alhaseeb, M.M.; Zaitone, S.A.; Abou-El-Ela, S.H.; Moustafa, Y.M. Olmesartan Potentiates the
Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich’s Ascites Carcinoma: Role of Angiotensin (1–7).
PLoS ONE 2014, 9, e85891. [CrossRef] [PubMed]
76. Liang, Y.; Brekken, R.A.; Hyder, S.M. Vascular endothelial growth factor induces proliferation of breast
cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr. Relat. Cancer 2006, 13,
905–919. [CrossRef] [PubMed]
77. Kumar, S.; Cieplak, P. Effect of phosphorylation and single nucleotide polymorphisms on caspase substrates
processing. Apoptosis 2018, 23, 194–200. [CrossRef] [PubMed]
Molecules 2019, 24, 3313 25 of 25
78. Hassan, M.; Watari, H.; AbuAlmaaty, A.; Ohba, Y.; Sakuragi, N. Apoptosis and Molecular Targeting Therapy
in Cancer. BioMed Res. Int. 2014, 2014, 150845. [CrossRef] [PubMed]
79. Cao, Z.; Yang, Q.; Yin, H.; Qi, Q.; Li, H.; Sun, G.; Wang, H.; Liu, W.; Li, J. Peroxynitrite induces apoptosis
of mouse cochlear hair cells via a Caspase-independent pathway in vitro. Apoptosis 2017, 22, 1419–1430.
[CrossRef] [PubMed]
80. Vance, N.R.; Gakhar, L.; Spies, M.A. Allosteric Tuning of Caspase-7: A Fragment-Based Drug Discovery
Approach. Angew. Chem. Int. Ed. Engl. 2017, 56, 14443–14447. [CrossRef] [PubMed]
81. Zahran, M.A.-H.; El-Aarag, B.; Mehany, A.B.M.; Belal, A.; Younes, A.S. Design, synthesis, biological
evaluations, molecular docking, and in vivo studies of novel phthalimide analogs. Arch. Pharm. Chem.
Life Sci. 2018, 351, 1–12. [CrossRef] [PubMed]
82. Salem, M.L.; Shoukry, N.M.; Teleb, W.K.; Abdel-Daim, M.M.; Abdel-Rahman, M.A. In vitro and in vivo
antitumor effects of the Egyptian scorpion Androctonus amoreuxi venom in an Ehrlich ascites tumor model.
SpringerPlus 2016, 5, 570. [CrossRef]
83. Marcelli, M.; Cunningham, G.R.; Walkup, M.; He, Z.; Sturgis, L.; Kagan, C.; Mannucci, R.; Nicoletti, I.;
Teng, B.; Denner, L. Signaling Pathway Activated during Apoptosis of the Prostate Cancer Cell Line LNCaP:
Overexpression of Caspase-7 as a New Gene Therapy Strategy for Prostate Cancer. Cancer Res. 1999, 59,
382–390. [PubMed]
84. Guirgis, A.A.; Zahran, M.; Mohamed, A.S.; Talaat, R.M.; Abdou, B.Y.; Agwa, H.S. Effect of thalidomide
dithiocarbamate analogs on the intercellular adhesion molecule-1 expression. Int. Immunopharmacol. 2010,
10, 805–811. [CrossRef] [PubMed]
85. Zahra, M.H.; Salem, T.A.; El-Aarag, B.; Yosri, N.; EL-Ghlban, S.; Zaki, K.; Marei, A.H.; Abd El-Wahed, A.;
Saeed, A.; Khatib, A.; et al. Alpinia zerumbet (Pers.): Food and Medicinal Plant with Potential In Vitro and In
Vivo Anti-Cancer Activities. Molecules 2019, 24, 2495. [CrossRef] [PubMed]
86. Papadopoulos, D.; Kimler, B.F.; Estes, N.C.; Durham, F.J. Growth delay effect of combined interstitial
hyperthermia and brachytherapy in a rat solid tumor model. Anticancer Res. 1989, 9, 45–47. [PubMed]
87. El-Aarag, B.; Hussein, W.; Ibrahim, W.; Zahran, M. Thymoquinone Improves Anti-Diabetic Activity of
Metformin in Streptozotocin-Induced Diabetic Male Rats. J. Diabetes Metab. 2017, 8, 780.
88. Chen, J.; Stavro, P.M.; Thompson, L.U. Dietary Flaxseed Inhibits Human Breast Cancer Growth and Metastasis
and Downregulates Expression of Insulin-Like Growth Factor and Epidermal Growth Factor Receptor.
Nutr. Cancer 2002, 43, 187–192. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are available from the authors.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
